May 4, 2022
Brian Culley is the CEO of Lineage Cell Therapeutics which is developing cell therapy for Dry AMD, a common condition and one of the leading causes of blindness, and to restore the functional capacity of hearing and the spine.
Brian explains, "Conceptually, what we're doing is manufacturing the type of cell that has...
May 4, 2022
Brian Culley is the CEO of Lineage Cell Therapeutics which is developing cell therapy for Dry AMD, a common condition and one of the leading causes of blindness, and to restore the functional capacity of hearing and the spine.
Brian explains, "Conceptually, what we're doing is manufacturing the type of cell that has...
Dec 1, 2021
Dr. Peter Altman is the President and CEO of BioCardia and emphasizes that heart disease is the leading cause of death in the Western world. BioCardia is developing technologies to treat cardiovascular diseases with cell and cell-derived therapies which allow for precise cell delivery in the heart and...
Dec 1, 2021
Dr. Peter Altman is the President and CEO of BioCardia and emphasizes that heart disease is the leading cause of death in the Western world. BioCardia is developing technologies to treat cardiovascular diseases with cell and cell-derived therapies which allow for precise cell delivery in the heart and...
Sep 22, 2020
Brian Culley, CEO, Lineage Cell Therapeutics talks about the risk we all face from developing age-related macular degeneration - both wet AMD and dry AMD. While there are treatments for wet AMD, currently there is no interventional approved treatment for dry AMD. Lineage is developing a ground-breaking treatment for dry...